← All trials
NCT05433272
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2022
- Primary completion
- Sep 10, 2023
- Completion date
- Sep 10, 2023
- First posted
- Jun 27, 2022
- Last posted
- Jun 27, 2022
- Enrollment
- 1400
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sinovac Biotech Co., LtdLead sponsor
- China National Pharmaceutical GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.